The utility of empirical mupirocin for eradication of methicillin-resistant Staphylococcus aureus colonisation in Far North Queensland, Australia

Authors

  • Isabel Guthridge Division of Medicine, Cairns Hospital, Cairns, Australia
  • Stuart Campbell Division of Medicine, Cairns Hospital, Cairns, Australia
  • Simon Smith Division of Medicine, Cairns Hospital, Cairns, Australia
  • Josh Hanson Division of Medicine, Cairns Hospital, Cairns, Australia; Kirby Institute, University of New South Wales, Sydney, Australia

DOI:

https://doi.org/10.33321/cdi.2023.47.9

Keywords:

mupirocin, Staphylococcus aureus, MRSA, decolonisation, Tropical Australia

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) infections are common in Far North Queensland (FNQ) and their incidence is increasing. Decolonisation regimens that include topical mupirocin are recommended in Australian guidelines to reduce recurrent infection. Mupirocin resistance was identified in 3,932/15,851 (24.8%) methicillin-sensitive Staphylococcus aureus (MSSA) isolates and in 533/5,134 (10.4%) MRSA isolates from FNQ between 1997 and 2016. Factors associated with mupirocin resistance in multivariate analysis were an MSSA isolate, age < 40 years, rural residence and female gender. These data support the use of mupirocin in MRSA decolonisation in FNQ, although addressing the underlying social determinants of health that drive the incidence of S. aureus infections remain a priority for local healthcare provision.

Downloads

Download data is not yet available.

References

Guthridge I, Smith S, Horne P, Hanson J. Increasing prevalence of methicillin-resistant Staphylococcus aureus in remote Australian communities: implications for patients and clinicians. Pathology. 2019;51(4):428–31. doi: https://doi.org/10.1016/j.pathol.2018.11.015.

Harch SAJ, MacMorran E, Tong SYC, Holt DC, Wilson J, Athan E et al. High burden of complicated skin and soft tissue infections in the Indigenous population of Central Australia due to dominant Panton Valentine leucocidin clones ST93-MRSA and CC121-MSSA. BMC Infect Dis. 2017;17(1):405. doi: https://doi.org/10.1186/s12879-017-2460-3.

von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med. 2001;344(1):11–6. doi: https://doi.org/10.1056/NEJM200101043440102.

Toshkova K, Annemüller C, Akineden O, Lämmler C. The significance of nasal carriage of Staphylococcus aureus as risk factor for human skin infections. FEMS Microbiol Lett. 2001;202(1):17–24. doi: https://doi.org/10.1111/j.1574-6968.2001.tb10774.x.

Turnidge JD. High burden of staphylococcal disease in indigenous communities. J Infect Dis. 2009;199(10):1416–8. doi: https://doi.org/10.1086/598219.

Therapeutic Guidelines. Recurrent staphylococcal skin infection. [Internet.] Melbourne: Therapeutic Guidelines Ltd.; April 2019. [Accessed on 12 March 2022.] Available from: https://tgldcdp.tg.org.au/viewTopic?topicfile=staphylococcal-skin-infection&guidelineName=Antibiotic#toc_d1e47.

Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):18–55. doi: https://doi.org/10.1093/cid/ciq146.

Huang SS, Singh R, McKinnell JA, Park S, Gombosev A, Eells SJ et al. Decolonization to reduce postdischarge infection risk among MRSA carriers. N Engl J Med. 2019;380(7):638–50. doi: https://doi.org/10.1056/NEJMoa1716771.

Australian Bureau of Statistics (ABS). Community Profiles. [Internet.] Canberra: ABS; 2017. [Accessed on 22 March 2022.] Available from: https://www.abs.gov.au/websitedbs/D3310114.nsf/Home/2016CensusCommunityProfiles.

Dadashi M, Hajikhani B, Darban-Sarokhalil D, van Belkum A, Goudarzi M. Mupirocin resistance in Staphylococcus aureus: a systematic review and meta-analysis. J Glob Antimicrob Resist. 2020;20:238–47. doi: https://doi.org/10.1016/j.jgar.2019.07.032.

Coombs GW, Daley DA, Lee YT, Pang S for the Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) Annual Report 2016. Commun Dis Intell (2018). 2018;42. PII: :S2209-6051(18)00021-0.

Patel JB, Gorwitz RJ, Jernigan JA. Mupirocin resistance. Clin Infect Dis. 2009;49(6):935–41. doi: https://doi.org/10.1086/605495.

Upton A, Lang S, Heffernan H. Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotic resistance. J Antimicrob Chemother. 2003;51(3):613–7. doi: https://doi.org/10.1093/jac/dkg127.

Bowen AC, Tong SYC, Chatfield MD, Carapetis JR. The microbiology of impetigo in Indigenous children: associations between Streptococcus pyogenes, Staphylococcus aureus, scabies, and nasal carriage. BMC Infect Dis. 2014;14:727. doi: https://doi.org/10.1186/s12879-014-0727-5.

Ray GT, Suaya JA, Baxter R. Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study. BMC Infect Dis. 2013;13:252. doi: https://doi.org/10.1186/1471-2334-13-252.

Bowen AC, Tong SYC, Andrews RM, O’Meara IM, McDonald MI, Chatfield MD et al. Short-course oral co-trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region: an open-label, randomised, controlled, non-inferiority trial. Lancet. 2014;384(9960):2132–40. doi: https://doi.org/10.1016/S0140-6736(14)60841-2.

Muir N, Bohr Y. Contemporary practice of traditional Aboriginal child rearing: a review. First Peoples Child & Family Review. 2020;9(1):66–79.

Tong SYC, Bishop EJ, Lilliebridge RA, Cheng AC, Spasova-Penkova Z, Holt DC et al. Community-associated strains of methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus in Indigenous northern Australia: epidemiology and outcomes. J Infect Dis. 2009;199(10):1461–70. doi: https://doi.org/10.1086/598218.

Allport J, Choudhury R, Bruce-Wootton P, Reed M, Tate D, Malviya A. Efficacy of mupirocin, neomycin and octenidine for nasal Staphylococcus aureus decolonisation: a retrospective cohort study. Antimicrob Resist Infect Control. 2022;11(1):5. doi: https://doi.org/10.1186/s13756-021-01043-1.

Phillips M, Rosenberg A, Shopsin B, Cuff G, Skeete F, Foti A et al. Preventing surgical site infections: a randomized, open-label trial of nasal mupirocin ointment and nasal povidone-iodine solution. Infect Control Hosp Epidemiol. 2014;35(7):826–32. doi: https://doi.org/10.1086/676872.

Downloads

Published

28/02/23

How to Cite

Guthridge, Isabel, Stuart Campbell, Simon Smith, and Josh Hanson. 2023. “The Utility of Empirical Mupirocin for Eradication of Methicillin-Resistant Staphylococcus Aureus Colonisation in Far North Queensland, Australia ”. Communicable Diseases Intelligence 47 (February). https://doi.org/10.33321/cdi.2023.47.9.

Issue

Vol. 47 (2023)

Section

Surveillance summary

Categories

License

Copyright (c) 2023 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)